Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis. Koh, J. H., Yoon, S. J., Kim, M., Cho, S., Lim, J., Park, Y., Kim, H., Kwon, S. W., & Kim, W. Experimental & Molecular Medicine, 54(2):143–155, February, 2022. Number: 2 Publisher: Nature Publishing Group![Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Lipid mediators are crucial for the pathogenesis of rheumatoid arthritis (RA); however, global analyses have not been undertaken to systematically define the lipidome underlying the dynamics of disease evolution, activation, and resolution. Here, we performed untargeted lipidomics analysis of synovial fluid and serum from RA patients at different disease activities and clinical phases (preclinical phase to active phase to sustained remission). We found that the lipidome profile in RA joint fluid was severely perturbed and that this correlated with the extent of inflammation and severity of synovitis on ultrasonography. The serum lipidome profile of active RA, albeit less prominent than the synovial lipidome, was also distinguishable from that of RA in the sustained remission phase and from that of noninflammatory osteoarthritis. Of note, the serum lipidome profile at the preclinical phase of RA closely mimicked that of active RA. Specifically, alterations in a set of lysophosphatidylcholine, phosphatidylcholine, ether-linked phosphatidylethanolamine, and sphingomyelin subclasses correlated with RA activity, reflecting treatment responses to anti-rheumatic drugs when monitored serially. Collectively, these results suggest that analysis of lipidome profiles is useful for identifying biomarker candidates that predict the evolution of preclinical to definitive RA and could facilitate the assessment of disease activity and treatment outcomes.
@article{koh_lipidome_2022,
title = {Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis},
volume = {54},
copyright = {2022 The Author(s)},
issn = {2092-6413},
url = {https://www.nature.com/articles/s12276-022-00725-z},
doi = {10.1038/s12276-022-00725-z},
abstract = {Lipid mediators are crucial for the pathogenesis of rheumatoid arthritis (RA); however, global analyses have not been undertaken to systematically define the lipidome underlying the dynamics of disease evolution, activation, and resolution. Here, we performed untargeted lipidomics analysis of synovial fluid and serum from RA patients at different disease activities and clinical phases (preclinical phase to active phase to sustained remission). We found that the lipidome profile in RA joint fluid was severely perturbed and that this correlated with the extent of inflammation and severity of synovitis on ultrasonography. The serum lipidome profile of active RA, albeit less prominent than the synovial lipidome, was also distinguishable from that of RA in the sustained remission phase and from that of noninflammatory osteoarthritis. Of note, the serum lipidome profile at the preclinical phase of RA closely mimicked that of active RA. Specifically, alterations in a set of lysophosphatidylcholine, phosphatidylcholine, ether-linked phosphatidylethanolamine, and sphingomyelin subclasses correlated with RA activity, reflecting treatment responses to anti-rheumatic drugs when monitored serially. Collectively, these results suggest that analysis of lipidome profiles is useful for identifying biomarker candidates that predict the evolution of preclinical to definitive RA and could facilitate the assessment of disease activity and treatment outcomes.},
language = {en},
number = {2},
urldate = {2023-06-07},
journal = {Experimental \& Molecular Medicine},
author = {Koh, Jung Hee and Yoon, Sang Jun and Kim, Mina and Cho, Seonghun and Lim, Johan and Park, Youngjae and Kim, Hyun-Sook and Kwon, Sung Won and Kim, Wan-Uk},
month = feb,
year = {2022},
note = {Number: 2
Publisher: Nature Publishing Group},
keywords = {Metabolomics, Rheumatoid arthritis},
pages = {143--155},
}
Downloads: 0
{"_id":"NWsMuMmX5MkBuW7x2","bibbaseid":"koh-yoon-kim-cho-lim-park-kim-kwon-etal-lipidomeprofilepredictiveofdiseaseevolutionandactivityinrheumatoidarthritis-2022","author_short":["Koh, J. H.","Yoon, S. J.","Kim, M.","Cho, S.","Lim, J.","Park, Y.","Kim, H.","Kwon, S. W.","Kim, W."],"bibdata":{"bibtype":"article","type":"article","title":"Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis","volume":"54","copyright":"2022 The Author(s)","issn":"2092-6413","url":"https://www.nature.com/articles/s12276-022-00725-z","doi":"10.1038/s12276-022-00725-z","abstract":"Lipid mediators are crucial for the pathogenesis of rheumatoid arthritis (RA); however, global analyses have not been undertaken to systematically define the lipidome underlying the dynamics of disease evolution, activation, and resolution. Here, we performed untargeted lipidomics analysis of synovial fluid and serum from RA patients at different disease activities and clinical phases (preclinical phase to active phase to sustained remission). We found that the lipidome profile in RA joint fluid was severely perturbed and that this correlated with the extent of inflammation and severity of synovitis on ultrasonography. The serum lipidome profile of active RA, albeit less prominent than the synovial lipidome, was also distinguishable from that of RA in the sustained remission phase and from that of noninflammatory osteoarthritis. Of note, the serum lipidome profile at the preclinical phase of RA closely mimicked that of active RA. Specifically, alterations in a set of lysophosphatidylcholine, phosphatidylcholine, ether-linked phosphatidylethanolamine, and sphingomyelin subclasses correlated with RA activity, reflecting treatment responses to anti-rheumatic drugs when monitored serially. Collectively, these results suggest that analysis of lipidome profiles is useful for identifying biomarker candidates that predict the evolution of preclinical to definitive RA and could facilitate the assessment of disease activity and treatment outcomes.","language":"en","number":"2","urldate":"2023-06-07","journal":"Experimental & Molecular Medicine","author":[{"propositions":[],"lastnames":["Koh"],"firstnames":["Jung","Hee"],"suffixes":[]},{"propositions":[],"lastnames":["Yoon"],"firstnames":["Sang","Jun"],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Mina"],"suffixes":[]},{"propositions":[],"lastnames":["Cho"],"firstnames":["Seonghun"],"suffixes":[]},{"propositions":[],"lastnames":["Lim"],"firstnames":["Johan"],"suffixes":[]},{"propositions":[],"lastnames":["Park"],"firstnames":["Youngjae"],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Hyun-Sook"],"suffixes":[]},{"propositions":[],"lastnames":["Kwon"],"firstnames":["Sung","Won"],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Wan-Uk"],"suffixes":[]}],"month":"February","year":"2022","note":"Number: 2 Publisher: Nature Publishing Group","keywords":"Metabolomics, Rheumatoid arthritis","pages":"143–155","bibtex":"@article{koh_lipidome_2022,\n\ttitle = {Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis},\n\tvolume = {54},\n\tcopyright = {2022 The Author(s)},\n\tissn = {2092-6413},\n\turl = {https://www.nature.com/articles/s12276-022-00725-z},\n\tdoi = {10.1038/s12276-022-00725-z},\n\tabstract = {Lipid mediators are crucial for the pathogenesis of rheumatoid arthritis (RA); however, global analyses have not been undertaken to systematically define the lipidome underlying the dynamics of disease evolution, activation, and resolution. Here, we performed untargeted lipidomics analysis of synovial fluid and serum from RA patients at different disease activities and clinical phases (preclinical phase to active phase to sustained remission). We found that the lipidome profile in RA joint fluid was severely perturbed and that this correlated with the extent of inflammation and severity of synovitis on ultrasonography. The serum lipidome profile of active RA, albeit less prominent than the synovial lipidome, was also distinguishable from that of RA in the sustained remission phase and from that of noninflammatory osteoarthritis. Of note, the serum lipidome profile at the preclinical phase of RA closely mimicked that of active RA. Specifically, alterations in a set of lysophosphatidylcholine, phosphatidylcholine, ether-linked phosphatidylethanolamine, and sphingomyelin subclasses correlated with RA activity, reflecting treatment responses to anti-rheumatic drugs when monitored serially. Collectively, these results suggest that analysis of lipidome profiles is useful for identifying biomarker candidates that predict the evolution of preclinical to definitive RA and could facilitate the assessment of disease activity and treatment outcomes.},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2023-06-07},\n\tjournal = {Experimental \\& Molecular Medicine},\n\tauthor = {Koh, Jung Hee and Yoon, Sang Jun and Kim, Mina and Cho, Seonghun and Lim, Johan and Park, Youngjae and Kim, Hyun-Sook and Kwon, Sung Won and Kim, Wan-Uk},\n\tmonth = feb,\n\tyear = {2022},\n\tnote = {Number: 2\nPublisher: Nature Publishing Group},\n\tkeywords = {Metabolomics, Rheumatoid arthritis},\n\tpages = {143--155},\n}\n\n","author_short":["Koh, J. H.","Yoon, S. J.","Kim, M.","Cho, S.","Lim, J.","Park, Y.","Kim, H.","Kwon, S. W.","Kim, W."],"key":"koh_lipidome_2022","id":"koh_lipidome_2022","bibbaseid":"koh-yoon-kim-cho-lim-park-kim-kwon-etal-lipidomeprofilepredictiveofdiseaseevolutionandactivityinrheumatoidarthritis-2022","role":"author","urls":{"Paper":"https://www.nature.com/articles/s12276-022-00725-z"},"keyword":["Metabolomics","Rheumatoid arthritis"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/ClinEpiLU","dataSources":["5jEuhQhgRx3py8LmG"],"keywords":["metabolomics","rheumatoid arthritis"],"search_terms":["lipidome","profile","predictive","disease","evolution","activity","rheumatoid","arthritis","koh","yoon","kim","cho","lim","park","kim","kwon","kim"],"title":"Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis","year":2022}